Product news

Share this article:
Schering-Plough said a committee of the European Medicines Agency has endorsed its drug sugammadex to reverse the effects of two muscle relaxants widely used in surgery. The committee's recommendations are typically adopted by European Union nations. Schering-Plough is still awaiting an FDA decision on sugammadex, which would be marketed in the US under the brand name Bridion. In a March, a FDA panel of experts unanimously voted in favor of approving the injectable drug. The agency is scheduled to make a final decision by early August. 

AstraZeneca has submitted a supplemental new drug application to the FDA for Nexium IV for injection to seek approval for use in patients with peptic ulcer bleeding following therapeutic endoscopy. 
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.